Stock fact sheet · data as of

Selectis Health, Inc. (GBCS): fair value, margin of safety and Wheel Score

Healthcare · Medical - Care Facilities · United States · Value

Close5.73
GLS fair value128.826 of 9 models
Margin of safety+96%price below fair value
Wheel Score39No optionscapped: no options
Health4/9Piotroski F-score
Moat1.7/10GLS 10-year score
Market cap$18M1k shares a day
Implied vol.-no listed options
P/E1.2EPS 4.75
Dividend yieldnone
Beta-1.30moves less than the market
Next earnings2 Dec 2026in 47 days

Is GBCS undervalued?

Selectis Health, Inc. (GBCS) closed at 5.73 on 16 Oct 2026. The GLS average fair value - the simple average of the 6 valuation models that produced a positive number - is 128.82, which puts the price 96% below it. 6 of the 6 models value the shares above the current price. A gap this wide is rare in our universe of ~7,400 US stocks and is exactly what the Value part of the Wheel Score rewards; it is also where the question "why is it this cheap?" matters most.

There is a wide gap between Graham Number (16.68) and GLS Growth (291.08). When the models are this far apart the "fair value" is really a range, and the margin of safety above should be read with that range in mind.

The nightly engine files GBCS under Value: positive earnings at a P/E of 18 or less.

Nine valuation models for GBCS

Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.

ModelValuevs priceWhat it measures
DCF21.49+275%Present value of the projected free cash flows, discounted at the cost of capital
Graham Number16.68+191%The most a defensive investor pays for the earnings and book value per share
Graham Growth271.97+4646%Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields
Lynch118.87+1974%EPS × the earnings growth rate (PEG of 1), growth capped at 25%
GLS Growth291.08+4980%EPS compounded ten years at the blended growth rate, discounted back at 15% a year
10 Cap--Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight
Payback Time--Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight
DDM--Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight
EPV52.83+822%Earnings power value: current EPS capitalised at 9% with no growth
Zombie (liquidation)-10.17-278%Current assets less all liabilities, per share: the balance-sheet floor. Not in the average
Wall St target0.0000-100%Analysts' average 12-month price target. Not in the average

Quality and financial health

Selectis Health, Inc. scores only 4 of 9 on the Piotroski F-score, which fails the Sunday Scan's "6 or more" rule. A reading this low means several of the basic tests - positive earnings, positive operating cash flow, falling debt, no new share issuance - are not met. A GLS Moat score of 1.7/10 is a weak reading: the ten-year history the score grades (revenue, EPS, book value, margins, cash flow, share count, ROIC) has not been steady, so the Moat part of the Wheel Score contributes little.

Returns on capital are thin or negative - ROIC -5.3%, ROE 16.4%, ROA -3.1% - with debt at -4.10 times equity and negative free cash flow.

Selectis Health, Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Health Care 98%, Management Fee Revenue 2% (quarter Q2 FY2026).

Institutional ownership scores 5/10, insider activity 10/10 and Congressional trading 5/10 on the GLS smart-money scales.

Piotroski F-score4 / 9ROIC-5.3%
GLS Moat1.7 / 10ROE16.4%
Debt / equity-4.10ROA-3.1%
Free-cash-flow yield-17.5%Payout ratio0%
Institutions5 / 10Insiders · Congress10 · 5 / 10

Wheel Score 39: No options

No options are listed on Selectis Health, Inc. in our nightly snapshot. The Wheel Score is therefore capped at 39 (it reads 39) and the stock is left out of every options screen; the fair value and health figures above are still useful for a plain stock position.

Volume runs at 1k shares a day on a market cap of $18M, with a beta of -1.30 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score gives that 6 of 20.

PartPointsFrom
Value25 / 2596% margin of safety
Health9 / 20Piotroski 4/9
Moat3 / 15moat 1.7/10
Premium0 / 20no option data
Stability6 / 201k shares/day, $18M cap, beta -1.30

The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.

Upcoming events

The next earnings report is due on 2 Dec 2026, 47 days away - outside the window of a 30-45-day put sold today.

Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.

Similar stocks in Medical - Care Facilities

The 12 companies below are the closest to Selectis Health, Inc. by market cap within the Medical - Care Facilities industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.

StockCloseFair valueMoSWheelMkt cap
PIII
P3 Health Partners Inc.
4.37--24No options$14M
RHEPB
Regional Health Properties, Inc.
6.2539,547.42+100%39No options$11M
DCGO
DocGo Inc.
0.2820--40Weak$28M
CCEL
Cryo-Cell International, Inc.
3.6511.97+69%39No options$29M
SYRA
Syra Health Corp. Class A Common Stock
0.84300.2255-274%14No options$10M
AMS
American Shared Hospital Services
1.266.91+82%39No options$8M
BICX
BioCorRx Inc.
0.2500--28No options$7M
EUDA
EUDA Health Holdings Limited
15.49--31No options$46M
HLYK
HealthLynked Corp.
2.20--25No options$6M
BTMD
biote Corp.
1.1111.26+90%39No options$49M
BMGL
Basel Medical Group Ltd Ordinary Shares
3.91--30No options$6M
RHEP
Regional Health Properties, Inc.
1.0231,975.90+100%39No options$4M

⚖ Compare GBCS with 7 of them   All Healthcare stocks →

Screen the whole market the same way

A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.

Start free See the Sunday Scan

Questions about GBCS

Is GBCS undervalued right now?

By the GLS models, yes: at 5.73 the stock is 96% below the average fair value of 128.82 (data as of 16 Oct 2026). Whether the discount is deserved is the question to research next.

What is the Wheel Score of GBCS and what does it mean?

GBCS has no listed options in our nightly snapshot, so it cannot be wheeled; its Wheel Score is capped at 39 and shown as "No options".

What is the GLS fair value for GBCS?

128.82 per share as of 16 Oct 2026 - the simple average of the 6 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.

When does Selectis Health, Inc. report earnings next?

The next earnings report is due on 2 Dec 2026, 47 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.

Does GBCS have listed options, and how liquid are they?

No. The nightly options snapshot found no listed contracts on GBCS, so the wheel strategy cannot be run on it and the Wheel Score is capped at 39.

Data as of 16 Oct 2026: prices and fundamentals from Financial Modeling Prep, option data from Polygon; valuations, scores and the Wheel Score by GLS Equity's models, run nightly. Prices in USD; the close shown is the previous session's. Everything on this page is general information produced by automated models from third-party data - not a recommendation to buy, sell or trade any security or option, and not financial advice. Past performance is not indicative of future results. GLS Equity provides data and tools, not financial advice.